- Home
- BBIO vs ESNT Comparison
BBIO vs ESNT Comparison
Compare BBIO & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ESNT
- Stock Information
- Founded
- BBIO 2015
- ESNT 2008
- Country
- BBIO United States
- ESNT Bermuda
- Employees
- BBIO N/A
- ESNT N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ESNT Property-Casualty Insurers
- Sector
- BBIO Health Care
- ESNT Finance
- Exchange
- BBIO Nasdaq
- ESNT Nasdaq
- Market Cap
- BBIO 6.7B
- ESNT N/A
- IPO Year
- BBIO 2019
- ESNT 2013
- Fundamental
- Price
- BBIO $34.37
- ESNT $57.86
- Analyst Decision
- BBIO Strong Buy
- ESNT Buy
- Analyst Count
- BBIO 12
- ESNT 7
- Target Price
- BBIO $57.09
- ESNT $61.71
- AVG Volume (30 Days)
- BBIO 3.2M
- ESNT 619.4K
- Earning Date
- BBIO 04-29-2025
- ESNT 05-09-2025
- Dividend Yield
- BBIO N/A
- ESNT 2.10%
- EPS Growth
- BBIO N/A
- ESNT 5.38
- EPS
- BBIO N/A
- ESNT 6.85
- Revenue
- BBIO $127,415,000.00
- ESNT $1,242,904,000.00
- Revenue This Year
- BBIO $13.67
- ESNT $3.71
- Revenue Next Year
- BBIO $118.02
- ESNT $4.58
- P/E Ratio
- BBIO N/A
- ESNT $8.60
- Revenue Growth
- BBIO N/A
- ESNT 12.00
- 52 Week Low
- BBIO $21.62
- ESNT $51.61
- 52 Week High
- BBIO $39.47
- ESNT $65.33
- Technical
- Relative Strength Index (RSI)
- BBIO 49.67
- ESNT 62.04
- Support Level
- BBIO $33.92
- ESNT $57.88
- Resistance Level
- BBIO $39.16
- ESNT $58.91
- Average True Range (ATR)
- BBIO 1.43
- ESNT 1.12
- MACD
- BBIO -0.16
- ESNT 0.33
- Stochastic Oscillator
- BBIO 31.05
- ESNT 72.83
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.